Pfizer has been granted authorization for the dual drug of Sansheng Guojian; Huashen Technology Received Administrative Supervision Measures Decision from Sichuan Securities Regulatory Bureau | Medical Early Reference

May 21, 2025  Source: drugdu 108

 

NO.1 Sancheng Guojian Dual Anti Drug Authorization Pfizer

SanSheng Guojian, an innovative pharmaceutical company on the Science and Technology Innovation Board, announced that the company and its affiliates SanSheng Pharmaceutical and Shenyang SanSheng Pharmaceutical Co., Ltd. have jointly granted Pfizer the exclusive development, production, and commercialization rights for the PD-1/VEGF bispecific antibody SSGJ-707 worldwide (excluding mainland China). It is reported that Pfizer will pay a non refundable and non deductible down payment of $1.25 billion, up to $4.8 billion in development, regulatory approval, and sales milestone payments, as well as a double-digit percentage gradient sales share calculated based on authorized regional product sales.

Comment: The "$1.25 billion down payment" of this authorization transaction once again breaks the record for the down payment amount of domestic innovative drugs going abroad, and also marks the recognition of the R&D strength of innovative drug companies on the Science and Technology Innovation Board by top international pharmaceutical companies, achieving another milestone for domestic pharmaceutical companies to enter the global market.

NO.2 YIFUXIN Acquires Partial Equity of Minority Shareholders in its Holding Subsidiary

Recently, the company announced that it held the 9th meeting of the 4th Board of Directors and the 9th meeting of the 4th Supervisory Board on May 16th, and approved the "Proposal on Acquiring Part of the Equity of the Minority Shareholders of the Holding Subsidiary and Related Party Transactions". In order to enhance the company's market equity in the Chinese market for the innovative drug AR882 and promote its efficient research and development and rapid listing, the company has agreed to sign an "Equity Transfer Agreement" between its wholly-owned subsidiary Ruiao Biotechnology and its partner Arthrosi. Ruiao Biotechnology plans to acquire 15.25% equity of the minority shareholder Arthrosi of the holding subsidiary Guangzhou Ruianbo with its own funds of 6.8 million US dollars (approximately 49 million yuan).

Comment: Attention should be paid to the subsequent clinical promotion and market access efficiency. The rationality of current transaction pricing and the sustainability of Arthrosi technology support remain to be observed.

NO.3 Huashen Technology receives the administrative supervision measures decision letter from Sichuan Securities Regulatory Bureau

Chengdu Huashen Technology Group Co., Ltd. (hereinafter referred to as the "Company") and its relevant responsible persons have recently received a decision from the Sichuan Regulatory Bureau of the China Securities Regulatory Commission (hereinafter referred to as the "Sichuan Securities Regulatory Bureau") to order Chengdu Huashen Technology Group Co., Ltd. to make corrections and issue warning letters to Huang Mingliang and other relevant responsible persons. After investigation, Huashen Technology has problems such as non-standard accounting, occupation of non operating funds, and incomplete internal control systems.

Comment: Huashen Technology has been ordered to rectify by the Sichuan Securities Regulatory Bureau due to issues such as non-standard financial accounting, internal control deficiencies, and related party fund occupation, exposing the risks of an incomplete corporate governance structure and weak compliance awareness. Regulatory oversight directly targets the responsibilities of executives such as the actual controller Huang Mingliang, reflecting the company's insufficient restraint on the behavior of major shareholders, which may affect the rights and interests of small and medium-sized investors.

NO.4 Resignation of CEO of Fosun Pharma's US subsidiary

Fosun Pharma announced that the board of directors has received a written resignation letter from Mr. Rong Yang. Mr. Rong Yang has applied to resign from his position as Senior Vice President due to personal reasons. Rong Yang joined Fosun Pharma in January 2022 as the CEO of Fosun Pharma USA. It is reported that the company is a wholly-owned subsidiary of Fosun Pharma established in the United States, and has formed the ability to commercialize generic drugs in the United States. Currently, it is further expanding its registration and commercialization capabilities for innovative drugs in the United States.

Comment: Considering the critical importance of Fosun Pharma's innovative drugs going global in the US market, attention should be paid to the selection of successors and strategic coherence. Short term personnel fluctuations do not change the long-term internationalization direction, but frequent changes in executives may slow down the pace of overseas expansion.

Disclaimer: The content and data in this article are for reference only and do not constitute investment advice. Please verify before use. Based on this operation, the risk is borne by oneself.

By editor
Share: 

your submission has already been received.

OK

Subscribe

Please enter a valid Email address!

Submit

The most relevant industry news & insight will be sent to you every two weeks.